JB170 is a highly specific PROTAC degrader of AURORA-A, created by connecting Alisertib to a Cereblon-binding molecule, Thalidomide. This compound selectively binds to AURORA-A, demonstrating a strong preference over AURORA-B. JB170 effectively induces S-phase arrest through targeted AURORA-A depletion, while also inhibiting its non-catalytic functions.
Usually ships within 24 hours.